NCT04609670View on ClinicalTrials.gov

Study of Radiolabeled ALXN2050 in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

August 23, 2021

Study Completion Date

August 23, 2021

Conditions
Healthy
Interventions
DRUG

[14C]-ALXN2050

A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.

Trial Locations (1)

68502

Clinical Trial Site, Lincoln

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY